Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$101.46 +1.38%

+$1.21 today

Market cap
$9.64B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 1.37M

Average 1.17M

SYRE Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Spyre Therapeutics, Inc.NASDAQ: SYRE

Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026

Cost of revenue remains negative

Q3 FY2026 cost of revenue was $0, compared with $45.25M a year earlier. Trailing-twelve-month cost of revenue was $45.25M.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $11.31M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$171.65M— YoY
LTMSep 2026
$45.25M+0.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
171.65M USD
Year-over-year change
—

Cost of Revenue vs competitors

How SYRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +0.0% is the 2nd highest of 6, against a peer median of -50.0%.
  • Cost of revenue amounts to 50.0% of revenue for SYRE, versus a peer median of 16.4%.
SYRE Competitors
Cost of Revenue for SYRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$45.25M USD+0.0%—50.0%
ARDXArdelyx, Inc.LTM Mar 2026$34.5M USD-39.4%+117.9%8.1%
IFRXInflaRx N.V.LTM Mar 2026€7.26M EUR+133.7%—24746.3%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$1.98M USD-86.0%-44.1%23.7%
UPBUpstream Bio, Inc.LTM Mar 2026$49K USD——1.5%
IMUXImmunic, Inc.LTM Mar 2026$33K USD-50.0%——
ABVXAbivax S.A.FY2025€0 EUR———
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€0 EUR———
ANABAnaptysBio, Inc.LTM Mar 2026-$38.15M USD-122.7%-69.9%16.4%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding SYRE) —-50.0%-44.1%16.4%

Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.74M2.33M886K00
Cost of Revenue0000171.65M
Gross Profit18.74M2.33M886K0(171.65M)
Gross Margin100.0%100.0%100.0%——
Research & Development57.07M58.58M89.5M162.79M171.65M
Selling, General & Admin27.32M28.53M39.95M45.78M47.91M
Operating Expenses84.39M87.11M243.19M208.57M37.91M
Depreciation & Amortization1.58M1.96M744K010M
EBITDA(64.08M)(81.99M)(127.82M)(207.97M)(209.56M)
EBITDA Margin-342.0%-3520.3%-14426.6%——
Operating Income(65.65M)(84.78M)(242.3M)(208.57M)(209.56M)
Operating Margin-350.3%-3640.2%-27348.0%——
Interest Income111K837K6.15M21.31M24.89M
Interest Expense00000
Other Income / Expenses(11K)830K(96.51M)599K54.34M
Income Before Tax(65.66M)(83.95M)(338.82M)(207.97M)(155.22M)
Pre-Tax Margin-350.4%-3604.6%-38241.1%——
Income Tax Expense141K(136K)(26K)51K(15K)
Net Income(65.8M)(83.82M)(338.79M)(208.02M)(155.2M)
Net Margin-351.1%-3598.8%-38238.1%——
EPS (Basic)(25.02)(24.86)(46.15)(3.18)(1.98)
EPS (Diluted)(25.02)(24.86)(46.15)(3.18)(1.98)
Weighted Avg Shares2.63M3.37M6.9M47.03M64.06M
Weighted Avg Shares (Diluted)2.63M3.37M6.9M47.03M64.06M

Spyre Therapeutics, Inc.

NASDAQ:SYRE

Intrinsic Alpha fair value

Locked

Current Price

$101.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.